Immix Biopharma

Immix Biopharma EBIT per Employee

The EBIT per Employee of Immix Biopharma (IMMX) as of Oct 31, 2026 is -1.43 M USD. In the previous year, EBIT per Employee was -1.08 M USD — a change of 32.11% (lower).

EBIT per Employee

-1.43 MUSD

YoY

32.11%

Last updated:

EBIT per Employee of Immix Biopharma is 2025 -1.43 M USD. EBIT per Employee of Immix Biopharma was 2024 -1.08 M USD. It decreases by 32.11% lower compared to the previous year.

The Immix Biopharma EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-40,119.00 USD
Jan 1, 2020
-21,612.00 USD
Jan 1, 2021
-1.15 M USD
Jan 1, 2022
-391,378.48 USD
Jan 1, 2023
-768,624.43 USD
Jan 1, 2024
-1.08 M USD
Jan 1, 2025
-1.43 M USD
The Immix Biopharma EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.43 MUSD+32.11%
-1.08 MUSD+40.48%
-768,624.43USD+96.39%
-391,378.48USD-66.03%
-1.15 MUSD+5,231.70%
-21,612.00USD-46.13%
-40,119.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immix Biopharma Stock analysis

What does Immix Biopharma do? Immix Biopharma, Inc. generates revenue through the development and commercialization of biopharmaceutical therapies targeting cancer and inflammatory diseases. The company's lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia, leveraging its TME Normalization Technology to simultaneously disable resistance pathways and induce tumor cell death. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease, respectively, with the company focusing on drug candidates that circulate in the bloodstream and target the tumor micro-environment. Immix Biopharma's primary buyers are pharmaceutical partners and potential licensees seeking innovative cancer and inflammatory disease treatments. The company's revenue streams are derived from clinical trial progress, potential future partnerships, and eventual product sales. IMX-110, as the lead asset, is central to the company's strategy, with its unique mechanism of action combining poly-kinase inhibition and apoptosis induction. The TME Normalization Technology enables drug candidates to effectively target the tumor micro-environment, enhancing therapeutic efficacy. Immix Biopharma's focus on solid tumors, colorectal cancer, and inflammatory bowel disease positions it within the oncology and gastroenterology segments of the biopharmaceutical market. Immix Biopharma's business model relies on advancing its pipeline through clinical trials to attract strategic partnerships and licensing agreements. The company's lead asset, IMX-110, is being tested for solid tumors, while IMX-111 and IMX-120 target specific disease areas. The company's technology platform, TME Normalization Technology, differentiates its drug candidates by enabling deep tumor micro-environment penetration. This approach aims to secure partnerships with larger pharmaceutical companies for further development and commercialization of its therapies. Immix Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immix Biopharma stock

EBIT per Employee of Immix Biopharma is -1.43 M USD in 2025.

EBIT per Employee of Immix Biopharma changed from -1.08 M USD to -1.43 M USD, representing a 32.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Immix Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Immix Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Immix Biopharma

All Key Metrics — Immix Biopharma